Equities

Merck Tbk PT

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MERK:JKT

Merck Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)3,200.00
  • Today's Change0.00 / 0.00%
  • Shares traded11.80k
  • 1 Year change-7.78%
  • Beta0.5789
Data delayed at least 10 minutes, as of Feb 13 2026 09:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PT Merck Tbk is an Indonesia-based company. The Company engages in the pharmaceutical industry, trading, leasing, and property management service. The Company operates through two segments, namely Biopharma and Consumer Health. The Biopharma segment focuses on ethical products, while the Consumer Health segment offers over-the-counter products. It manufactures and sells various pharmaceutical products, including finished products, bulk products, active ingredients, and other materials. The Company serves customers in Indonesia and offshore countries.

  • Revenue in IDR (TTM)1.10tn
  • Net income in IDR178.51bn
  • Incorporated1970
  • Employees369.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Infant Bacterial Therapeutics AB0.00-150.38bn1.38tn10.00--6.11-----5.92-5.920.009.230.00----0.00-38.19-22.82-48.56-24.41------------0.00-------11.24------
Vetnostrum Animal Health Co Ltd733.14bn64.03bn1.41tn185.0020.752.0113.561.921.741.7419.7717.950.91652.786.487,399,816.008.007.649.8110.1031.8531.008.739.192.1873.650.017449.577.173.6849.153.98-30.60--
Merck Tbk PT1.10tn178.51bn1.43tn369.008.031.726.461.31398.45398.452,448.931,859.851.151.746.552,917,872,000.0018.7414.6521.7118.9340.1539.7216.2714.773.79--0.017973.427.836.84-13.9014.42-10.515.51
Accent Microcell Ltd516.50bn64.42bn1.43tn192.0021.123.0919.842.7815.2415.24122.20104.071.124.145.3214,474,330.0013.99--15.95--39.96--12.47--3.0176.480.0046--7.77--9.60------
Inter Pharma PCL1.17tn60.70bn1.44tn162.0023.781.3111.101.240.1850.1853.563.360.69623.646.8913,293,500.004.003.985.345.1940.5240.405.756.011.237.920.154923.266.5238.23-26.60-3.03160.41--
Uni-Bio Science Group Ltd1.27tn196.70bn1.48tn504.007.551.796.001.160.01520.01520.09760.06411.133.629.181,210,657.0017.516.2122.178.5682.1980.7215.494.963.2259.390.221,633.5814.0821.4316.79102.0432.65--
Fusen Pharmaceutical Co Ltd587.73bn-426.73bn1.48tn1.05k--1.75--2.52-0.2681-0.26810.36920.53090.18751.114.05241,331.70-13.62-2.83-32.04-5.4041.3951.61-72.61-8.000.4241-0.43440.5137---42.36-4.36-420.39---17.55--
Remus Pharmaceuticals Ltd1.39tn60.51bn1.48tn68.0021.782.6018.151.0731.1131.11701.20260.511.899.077.21109,981,700.0010.4414.3718.4428.6013.0119.395.518.391.0735.590.04523.59191.93120.4434.98104.5648.07--
Data as of Feb 13 2026. Currency figures normalised to Merck Tbk PT's reporting currency: Indonesian Rupiah IDR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.